ESH CLL 2022 – Pierre Feugier

Pierre Feugier explains which patients with CLL should preferably be treated with targeted agents rather than with chemotherapy or chemoimmunotherapy, the advantages of second-generation BTK inhibitors as compared to first-generation BTK inhibitors and discusses third-generation BTK inhibitors as well as his personal highlights reported at ESH CLL 2022.

Here is the full ESH CLL 2022 report.